| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
|
Evens, A.M.
|
|
|
24 |
12 |
p. 3076-3081
|
article
|
| 2 |
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
|
Lim, S.M.
|
|
|
24 |
12 |
p. 3089-3094
|
article
|
| 3 |
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma
|
Hay, A.E.
|
|
|
24 |
12 |
p. 3065-3069
|
article
|
| 4 |
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
|
Sohal, D.P.S.
|
|
|
24 |
12 |
p. 3061-3065
|
article
|
| 5 |
Associations of bread and pasta with the risk of cancer of the breast and colorectum
|
Augustin, L.S.A.
|
|
|
24 |
12 |
p. 3094-3099
|
article
|
| 6 |
A structured approach to uncommon cancers: what should a clinician do?
|
Raghavan, D.
|
|
|
24 |
12 |
p. 2932-2934
|
article
|
| 7 |
β-Blocker usage and colorectal cancer mortality: a nested case–control study in the UK Clinical Practice Research Datalink cohort
|
Hicks, B.M.
|
|
|
24 |
12 |
p. 3100-3106
|
article
|
| 8 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial
|
Pierga, J.-Y.
|
|
|
24 |
12 |
p. 2999-3004
|
article
|
| 9 |
Clinical biomarkers of response in advanced renal cell carcinoma
|
Ravaud, A.
|
|
|
24 |
12 |
p. 2935-2942
|
article
|
| 10 |
Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study
|
Watson, S.
|
|
|
24 |
12 |
p. 3035-3039
|
article
|
| 11 |
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma
|
Kim, S.
|
|
|
24 |
12 |
p. 3045-3050
|
article
|
| 12 |
Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis
|
Kiderlen, M.
|
|
|
24 |
12 |
p. 3011-3016
|
article
|
| 13 |
Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient
|
Hoefnagel, L.D.C.
|
|
|
24 |
12 |
p. 3017-3023
|
article
|
| 14 |
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer †
|
Falchook, G.S.
|
|
|
24 |
12 |
p. 3004-3011
|
article
|
| 15 |
Editorial board
|
|
|
|
24 |
12 |
p. ii-iii
|
article
|
| 16 |
Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients
|
Ganci, F.
|
|
|
24 |
12 |
p. 3082-3088
|
article
|
| 17 |
Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531)
|
Mocellin, S.
|
|
|
24 |
12 |
p. 3040-3044
|
article
|
| 18 |
Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy † † This study was presented in part (as oral presentations) at the 10th Meeting of the European Association of NeuroOncology (EANO), 6–9 September 2012, Marseille, France and at the 2012 Annual Meeting of the Society for NeuroOncology (SNO), 15–18 November 2012, Washington, DC, USA.
|
Kreth, F. -W.
|
|
|
24 |
12 |
p. 3117-3123
|
article
|
| 19 |
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab
|
Sclafani, F.
|
|
|
24 |
12 |
p. 3123-3128
|
article
|
| 20 |
Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions
|
Klimm, B.
|
|
|
24 |
12 |
p. 3070-3076
|
article
|
| 21 |
Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials
|
Qi, W.-X.
|
|
|
24 |
12 |
p. 2943-2952
|
article
|
| 22 |
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
|
Guarneri, V.
|
|
|
24 |
12 |
p. 2990-2994
|
article
|
| 23 |
Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) † † The study was previously presented as an oral presentation at the 33rd Annual Meeting of the American Society of Clinical Oncology; 3–5 June 2011; Chicago, IL, USA.
|
Gerber, B.
|
|
|
24 |
12 |
p. 2978-2984
|
article
|
| 24 |
No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy
|
Bernards, N.
|
|
|
24 |
12 |
p. 3056-3060
|
article
|
| 25 |
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial † † Data from this study were presented in part at the 2013 Genitourinary Cancer Symposium, Orlando, FL, February 14–16.
|
Procopio, G.
|
|
|
24 |
12 |
p. 2967-2971
|
article
|
| 26 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial
|
de Azambuja, E.
|
|
|
24 |
12 |
p. 2985-2989
|
article
|
| 27 |
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data
|
Raja, F.A.
|
|
|
24 |
12 |
p. 3028-3034
|
article
|
| 28 |
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group
|
Giessen, C.
|
|
|
24 |
12 |
p. 3051-3055
|
article
|
| 29 |
Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube
|
Sehouli, J.
|
|
|
24 |
12 |
p. 3024-3028
|
article
|
| 30 |
Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer
|
Dekker, T.J.A.
|
|
|
24 |
12 |
p. 2994-2998
|
article
|
| 31 |
Red meat and cancer risk in a network of case–control studies focusing on cooking practices
|
Di Maso, M.
|
|
|
24 |
12 |
p. 3107-3112
|
article
|
| 32 |
Response to Evens et al., Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis, Annals of Oncology 23: 2128–2137, 2012
|
Glaser, S.L.
|
|
|
24 |
12 |
p. 3136
|
article
|
| 33 |
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
|
Reid, G.
|
|
|
24 |
12 |
p. 3128-3135
|
article
|
| 34 |
Suicide and suicide attempt after a cancer diagnosis among young individuals
|
Lu, D.
|
|
|
24 |
12 |
p. 3112-3117
|
article
|
| 35 |
Table of Contents
|
|
|
|
24 |
12 |
p. iv-vi
|
article
|
| 36 |
Thank you my friends
|
Vermorken, J.B.
|
|
|
24 |
12 |
p. 2931
|
article
|
| 37 |
Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis
|
Hourdequin, K.C.
|
|
|
24 |
12 |
p. 2952-2962
|
article
|
| 38 |
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials*
|
Templeton, A.J.
|
|
|
24 |
12 |
p. 2972-2977
|
article
|
| 39 |
Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma
|
Pécuchet, N.
|
|
|
24 |
12 |
p. 2963-2967
|
article
|
Journal description